Novartis Oncology
Global pharmaceutical company with capabilities spanning biologics and small-molecule R&D, clinical development, regulatory submissions, and multi-site manufacturing for advanced therapies (including cell, gene and radioligand therapies). Also operates global health and foundation programs focused on access, digital health, data/AI and impact valuation, and runs patient support and community health initiatives in low- and middle-income countries.
Industries
N/A
Services
Commercial CAR-T manufacturing services
Regional commercial manufacturing and supply of autologous CAR-T therapies from approved European sites to support clinical and commercial patients.
Radioligand therapy commercial production
Commercial-scale radioligand therapy manufacturing from multiple approved sites with phased capacity ramp-up to support US and EU markets.
Novartis Access: low-cost medicine portfolio program
Program to supply a defined portfolio of essential medicines at reduced cost to public-sector purchasers in low- and middle-income countries, combined with capacity-building activities.
Patient support program (Prayaas) for diabetes
Community health camps, digital monitoring tools and online services to improve diagnosis, adherence and long-term disease management for people with diabetes.
Communities for Healthy Hearts hypertension program
Community-based hypertension screening, updated local treatment guidelines, healthcare professional training and mobile reminders to improve blood pressure control in urban districts.
Digital, data and AI global health initiatives (Foundation)
Programs focused on applying data, digital platforms and AI to improve global health program design, delivery and evaluation.
Commercial CAR-T manufacturing services
Regional commercial manufacturing and supply of autologous CAR-T therapies from approved European sites to support clinical and commercial patients.
Radioligand therapy commercial production
Commercial-scale radioligand therapy manufacturing from multiple approved sites with phased capacity ramp-up to support US and EU markets.
Novartis Access: low-cost medicine portfolio program
Program to supply a defined portfolio of essential medicines at reduced cost to public-sector purchasers in low- and middle-income countries, combined with capacity-building activities.
Patient support program (Prayaas) for diabetes
Community health camps, digital monitoring tools and online services to improve diagnosis, adherence and long-term disease management for people with diabetes.
Communities for Healthy Hearts hypertension program
Community-based hypertension screening, updated local treatment guidelines, healthcare professional training and mobile reminders to improve blood pressure control in urban districts.
Digital, data and AI global health initiatives (Foundation)
Programs focused on applying data, digital platforms and AI to improve global health program design, delivery and evaluation.
Expertise Areas
- CAR-T manufacturing
- Radioligand therapy manufacturing
- Cell and gene therapy development
- Oncology clinical development
Key Technologies
- CAR-T cell therapy manufacturing
- Cell and gene therapy platforms
- Radioligand therapy (Lutetium-177 based)
- Allosteric kinase inhibitors (STAMP/allosteric inhibitors)